Clinical trial
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by…
NCT00392691 · Swiss Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00392691 |
|---|---|
| Title | Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment |
| Official title | Ibritumomab Tiuxetan and High-Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation for Elderly Patients With Lymphoma in Relapse or Resistant to Chemotherapy. A Multicenter Phase I Trial |
| Lead sponsor | Swiss Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | ibritumomab tiuxetan, rituximab, melphalan, vinorelbine tartrate / G-CSF, autologous hematopoietic stem cell harvesting and transplantation |
| Enrollment | 20 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2012 |
| Completion | May 1, 2013 |
| First posted | Oct 26, 2006 |
| Last update posted | May 15, 2019 |
| Countries | Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: